These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 34462985)

  • 21. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
    Lüscher B; Möhler H
    F1000Res; 2019; 8():. PubMed ID: 31275559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine insights into neurosteroid therapy for postpartum depression.
    Reddy DS
    Trends Mol Med; 2023 Dec; 29(12):979-982. PubMed ID: 37541828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel neurosteroid therapeutics for post-partum depression: perspectives on clinical trials, program development, active research, and future directions.
    Patterson R; Balan I; Morrow AL; Meltzer-Brody S
    Neuropsychopharmacology; 2024 Jan; 49(1):67-72. PubMed ID: 37715106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exploring the clinical potentials of zuranolone in managing postpartum depression: A new therapeutic horizon.
    Nashwan AJ; Rehan ST; Imran L; Abbas SG; Khan SF
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jun; 132():110983. PubMed ID: 38412941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
    Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
    J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GABA
    Luscher B; Maguire JL; Rudolph U; Sibille E
    Trends Pharmacol Sci; 2023 Sep; 44(9):586-600. PubMed ID: 37543478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progesterone loading as a strategy for treating postpartum depression.
    Barak Y; Glue P
    Hum Psychopharmacol; 2020 May; 35(3):e2731. PubMed ID: 32250509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relating neurosteroid modulation of inhibitory neurotransmission to behaviour.
    Belelli D; Phillips GD; Atack JR; Lambert JJ
    J Neuroendocrinol; 2022 Feb; 34(2):e13045. PubMed ID: 34644812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)
    Martinez Botella G; Salituro FG; Harrison BL; Beresis RT; Bai Z; Blanco MJ; Belfort GM; Dai J; Loya CM; Ackley MA; Althaus AL; Grossman SJ; Hoffmann E; Doherty JJ; Robichaud AJ
    J Med Chem; 2017 Sep; 60(18):7810-7819. PubMed ID: 28753313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staying Up to Date With Evolving Postpartum Depression Pathophysiology and Treatment Research.
    Deligiannidis KM; Vaughn R
    J Clin Psychiatry; 2023 Aug; 84(4):. PubMed ID: 37585246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurosteroid Modulation of Synaptic and Extrasynaptic GABA
    Mitchell SJ; Phillips GD; Tench B; Li Y; Belelli D; Martin SJ; Swinny JD; Kelly L; Atack JR; Paradowski M; Lambert JJ
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
    Faden J; Citrome L
    Ther Adv Psychopharmacol; 2020; 10():2045125320968658. PubMed ID: 33224470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD.
    Deligiannidis KM; Clayton AH
    J Clin Psychiatry; 2023 Mar; 84(Suppl 1):. PubMed ID: 36928484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brexanolone to Treat Postpartum Depression in Adult Women.
    Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis.
    Winslow M; White E; Rose SJ; Salzer E; Nemec EC
    Int J Clin Pharm; 2024 Jun; 46(3):590-601. PubMed ID: 38489051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Realising the therapeutic potential of neuroactive steroid modulators of the GABA
    Belelli D; Hogenkamp D; Gee KW; Lambert JJ
    Neurobiol Stress; 2020 May; 12():100207. PubMed ID: 32435660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond.
    Zorumski CF; Paul SM; Covey DF; Mennerick S
    Neurobiol Stress; 2019 Nov; 11():100196. PubMed ID: 31649968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.